EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Tumor Suppressor microRNAs as Potential Treatment Therapeutics for Advanced Medulloblastoma

Chanlee Luu, Gabriel Salyer, Linda Gerace, Maryam Abdul-Kader, Ava Azizi, Alan Mariño del Puerto, Param Thakkar, Yvonne Chen, Jill Ivory, Rebecca Amrick, Martina Novajas, Evan Schnieder und 1 weitere

Journal of Cancer Biomoleculars and Therapeutics · 2025

DOI: 10.62382/jcbt.v2i1.31 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cancer Biomoleculars and Therapeutics, 2025. Verfasst von Chanlee Luu und 12 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Medulloblastoma (MB) is one of the most prevalent forms of malignant brain cancer observed within pediatric patients and is particularly difficult to diagnose and treat due to the anatomical localization of tumors near the brainstem. Currently, there are four molecular classifications of MBL: WNT, SHH, Group 3, and Group 4 tumor subgroups. Wingless-type (WNT) mutant tumors are the least common, often caused by mutations in the CTNNB1 gene that plays a crucial role in the wingless cell signaling pathway, yet associates with the best prognosis as compared to all other MBL subtypes. Sonic hedgehog (SHH) mutant tumors arise due to continued release of Shh from purkinje cells, and an uninhibited proliferation response by granular neuronal precursors (GNPs). Group 3 and 4 MBL subgroups are still a molecularly heterogeneous class of tumors, with Group 3 MBL being highly associated with metastasis upon diagnosis, and more prevalently characterized by MYC amplification and activation. Group 4 MBL tumors comprise approximately 40% of all MBL, and remain remarkably heterogeneous with respect to somatic mutations of genes such as KDM6A, OTX2, ZMYM3, with an approximate 80% of tumors harboring chromosome 17 copy number alterations. While a majority of MBL cases cannot be linked to a single protein coding gene alteration, the role of non-coding RNAs, such as miRNAs, seems quite promising as a genetic marker to further sub-categorize MBL at the molecular level. Furthermore, miRNA-based therapy is proving to be a promising treatment to curb the growth of a number of cancer types within the clinic, with particular miRNAs under investigation including miR-34a, miR-211, and miR-584-5p. These miRNAs are known to induce cell cycle arrest in mouse models and demonstrate anti-tumorigenic properties in vitro, meriting further investigation of miRNA-based clinical trials for pediatric MBL patients.

Zitieren

APA

Luu, C., Salyer, G., Gerace, L., Abdul-Kader, M., Azizi, A., Puerto, A. M. D., Thakkar, P., Chen, Y., Ivory, J., Amrick, R., Novajas, M., Schnieder, E., & Adams, B. D. (2025). Tumor Suppressor microRNAs as Potential Treatment Therapeutics for Advanced Medulloblastoma. Journal of Cancer Biomoleculars and Therapeutics. https://doi.org/10.62382/jcbt.v2i1.31

Vancouver

Luu C, Salyer G, Gerace L, Abdul-Kader M, Azizi A, Puerto AMD, et al. Tumor Suppressor microRNAs as Potential Treatment Therapeutics for Advanced Medulloblastoma. Journal of Cancer Biomoleculars and Therapeutics. 2025. doi:10.62382/jcbt.v2i1.31

BibTeX
@article{Luu2025,
  author = {Luu, Chanlee and Salyer, Gabriel and Gerace, Linda and Abdul-Kader, Maryam and Azizi, Ava and Puerto, Alan Mariño del and Thakkar, Param and Chen, Yvonne and Ivory, Jill and Amrick, Rebecca and Novajas, Martina and Schnieder, Evan and Adams, Brian D.},
  title = {Tumor Suppressor microRNAs as Potential Treatment Therapeutics for Advanced Medulloblastoma},
  journal = {Journal of Cancer Biomoleculars and Therapeutics},
  year = {2025},
  doi = {10.62382/jcbt.v2i1.31}
}
Kostenlos starten →